Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseases

Internal Medicine

Volumn 48, Issue 22, 2009, Pages 1931-1938

  Kameda, Hideto ^a   Amano, Koichi ^a   Nagasawa, Hayato ^a   Ogawa, Hiroe ^a   Sekiguchi, Naoya ^a   Takei, Hirofumi ^a   Suzuki, Katsuya ^a   Takeuchi, Tsutomu ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Aseptic necrosis; Corticosteroids; Osteoporosis; Systemic lupus erythematosus

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ETIDRONIC ACID; GLUCOCORTICOID; PREDNISOLONE;

ADULT; ARTICLE; BONE DENSITY; BONE RADIOGRAPHY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FEMUR HEAD NECROSIS; HUMAN; LUMBAR SPINE; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMENOPAUSE; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC DISEASE; URINARY EXCRETION; VERTEBRA FRACTURE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; FEMUR HEAD NECROSIS; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PREDNISOLONE; RHEUMATIC DISEASES; RISK FACTORS; SPINAL FRACTURES;

EID: 71049165615     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2414     Document Type: Article

References (47)

1. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112: 352-364, 1990.
2. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporosis Int 11: 556-561, 2000. (Pubitemid 30739877)
3. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15: 993-1000, 2000. (Pubitemid 30350061)
4. Bone and Tooth Society, National Osteoporosis Society, Royal College of Physicians. Glucocorticoid-induced Osteoporosis : Guidelines for Prevention and Treatment. Royal College of Physicians, London, 2002.
5. American College of Rheumatology ad hoc Committee on Glucocorticoid- induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 44: 1496-1503, 2001.
6. Nawata H, Soen S, Takayanagi R, et al; The Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis: Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral research (2004). J Bone Miner Metab 23: 105-109, 2005.
7. van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13: 777-787, 2000.
8. Geusens PP, de Nijs RNJ, Lems WF, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 63: 324-325, 2004.
9. Nzeusseu Toukap A, Depresseux G, Devogelaer JP, Houssiau FA. Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients. Lupus 14: 517-520, 2005. (Pubitemid 41161081)
10. Okada Y, Nawata M, Nakayamada S, Saito K, Tanaka Y. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. J Rheumatol 35: 2249-2254, 2008.
11. Mok CC, Tong KH, To CH, Siu YP, Ma KM. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. Osteoporosis Int 19: 937-941, 2008.
12. Tatsuno I, Suzuki S, Yoshida T, Tanaka T, Sueishi M, Sugiyama T. High prevalence and early complication of symptomatic vertebral fracture in elderly people treated with high-dose glucocorticoids. J Am Geriatr Soc 57: 188-189, 2009.
13. Nakayamada S, Okada Y, Saito K, Tanaka Y. Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. J Rheumatol 31: 163-166, 2004. (Pubitemid 38067539)
14. Kumagai S, Kawano S, Atsumi T, et al. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases. J Rheumatol 32: 863-869, 2005. (Pubitemid 40676497)
15. Abu-Shakra M, Buskila D, Shoenfeld Y. Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol 25: 13-23, 2003.
16. Oinuma K, Harada Y, Nawata Y, et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 60: 1145-1148, 2001. (Pubitemid 33096080)
17. Nagasawa K, Tada Y, Koarada S, et al. Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 14: 385-390, 2005. (Pubitemid 40756448)
18. Nagasawa K, Tada Y, Koarada S, et al. Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant. Lupus 15: 354-357, 2006. (Pubitemid 44032710)
19. Fialho SC, Bonfá E, Vitule LF, et al. Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus 16: 239-244, 2007. (Pubitemid 46797886)
20. Dovio A, Perazzolo L, Osella G, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 89: 4923-4928, 2004. (Pubitemid 39391429)
21. Lane NE. Therapy insight: osteoporosis and osteonecrosis in systemic lupus erythematosus. Nat Clin Pract Rheumatol 2: 562-569, 2006. (Pubitemid 44489960)
22. Weinstein RS, Jilka RL, Parfitt M, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102: 274-282, 1998.
23. Zalavras C, Shah S, Birnbaum MJ, Frenkel B. Role of apoptosis in glucocorticoid-induced osteoporosis and osteonecrosis. Crit Rev Eukarot Gene Express 13: 221-235, 2003. (Pubitemid 38009171)
24. Calder JDF, Buttery L, Revell PA, Pearse M, Polak JM. Apoptosis - a significant cause of bone cell death in osteonecrosis of the femoral head. J Bone Joint Surg 86-B: 1209-1213, 2004. (Pubitemid 39545614)
25. Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19: 331-337, 2000.
26. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15: 721-739, 2000. (Pubitemid 30174026)
27. Jardinet D, Lefébvre C, Depresseux G, Lambert M, Devogelaer JP, Houssiau FA. Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology 39: 389-392, 2000. (Pubitemid 30307324)
28. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48: 3224-3229, 2003. (Pubitemid 37409336)
29. Yee C-S, Crabtree N, Skan J, et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 64: 111-113, 2005. (Pubitemid 40075285)
30. Sato S, Ohosone Y, Suwa A, et al. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. J Rheumatol 30: 2673-2679, 2003. (Pubitemid 37549348)
31. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337: 382-387, 1997. (Pubitemid 27328368)
32. Smith FE, Sweet DE, Brunner CM, Davis IV JS. Avascular necrosis in SLE. An apparent predilection for young patients. Ann Rheum Dis 35: 227-232, 1976.
33. Zizic TM, Marcoux C, Hungerford DS, Dansereau J-V, Stevens MB. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 79: 596-604, 1985. (Pubitemid 16191213)
34. Ono K, Tohjima T, Komazawa T. Risk factors of avascular necrosis of the femoral head in patients with systemic lupus erythematosus under high-dose corticosteroid therapy. Clin Orthop Relat Res 277: 89-97, 1992.
35. Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24: 654-662, 1997. (Pubitemid 27146080)
36. Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol 28: 761-765, 2001. (Pubitemid 32246943)
37. Prasad R, Ibanez D, Gladman D, Urowitz M. The role of noncorticosteroid factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients. Lupus 16: 157-162, 2007. (Pubitemid 46506591)
38. Reid IR, Evans MC, Stapleton J. Lateral spine densitometry is a more sensitive indicator of glucocorticoid-induced bone loss. J Bone Miner Res 7: 1221-1225, 1992.
39. Finkelstein JS, Cleary RL, Butler JP, et al. A comparison of lateral versus anterior-posterior spine dual energy x-ray absorptiomatry for the diagnosis of osteopenia. J Clin Endocrnol Metab 78: 724-730, 1994.
40. Vande Berg BC, Malghem J, Lecouvet FE, Devogelaer J-P, Maldague B, Houssiau FA. Fat conversion of femoral marrow in glucocorticoid-treated patients. A cross-sectional and longitudinal study with magnetic resonance imaging. Arthritis Rheum 42: 1405-1411, 1999.
41. Ichiseki T, Ueda Y, Katsuda S, Kitamura K, Kaneuji A, Matsumoto T. Oxidative stress by glutathione depletion induces osteonecrosis in rats. Rheumatology 45: 287-290, 2006. (Pubitemid 43372842)
42. Liu Y-F, Chen W-M, Lin Y-F, et al. Type II collagen gene variants and inherited osteonecrosis of the femoral head. N Engl J Med 352: 2294-2301, 2005. (Pubitemid 40740553)
43. Wu X, Yang S, Duan D, Zhang Y, Wang J. Experimental osteonecrosis induced by a combination of low-dose lipopolysaccharide and high-dose methylprednisolone in rabbits. Joint Bone Spine 75: 573-578, 2008.
44. Saag KG, Emkey R, Schnitzer TJ, et al; For the Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339: 292-299, 1998.
45. de Nijs RNJ, Jacobs JWG, Lems WF, et al; For the STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355: 675-684, 2006.
46. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42: 2309-2318, 1999.
47. Reid DM, Hughes RA, Laan RFJM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. J Bone Miner Res 15: 1006-1013, 2000.